A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia

Trial Profile

A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Vadastuximab talirine (Primary) ; Azacitidine; Azacitidine; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 25 Jul 2018 Results (n=53) assessing safety, tolerability and acitivity of vadastuximab talirine with HMA published in the Blood
    • 03 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 25 Jun 2017 Results (n=53) of 33A+HMA cohort, presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top